OXAZEPAM Drug Interactions
Also known as: Oxazepam
OXAZEPAM (brand name: Oxazepam) is a Benzodiazepines. used to treat anxiety disorders, insomnia, seizures, and alcohol withdrawal.OXAZEPAM has 10 documented drug interactions in our database, including 6 contraindicated, 4 major, 0 moderate, and 0 minor interactions.
6
Contraindicated
4
Major
0
Moderate
0
Minor
The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypotension, and psychomotor impairment.
Mechanism
Buprenorphine, a partial opioid agonist, and oxazepam, a benzodiazepine, both exert central nervous system (CNS) depressant effects. Their co-administration leads to an additive pharmacodynamic interaction, significantly enhancing GABAergic inhibition and opioid receptor activation, thereby profoundly depressing CNS and respiratory function.
Clinical Management
Concomitant use of buprenorphine and oxazepam is generally contraindicated due to the high risk of severe adverse outcomes, including death. If co-administration is absolutely necessary and no alternatives exist, it should be done with extreme caution, initiating with the lowest possible doses of both drugs, for the shortest duration, and with close monitoring for respiratory depression and sedation. Consider naloxone availability and educate patients on signs of overdose.
Concomitant use significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased respiratory rate, shallow breathing, hypoxemia, unresponsiveness, and circulatory collapse.
Mechanism
Fentanyl, an opioid agonist, and oxazepam, a benzodiazepine, both exert central nervous system (CNS) depressant effects. The co-administration leads to additive pharmacodynamic depression of the CNS, particularly affecting the respiratory drive and level of consciousness.
Clinical Management
Avoid co-prescription of fentanyl and oxazepam due to the high risk of severe adverse outcomes, including death. If concurrent use is unavoidable, use the lowest effective doses for the shortest possible duration, monitor patients closely for respiratory depression and sedation, and ensure naloxone is readily available. Consider alternative treatments that do not carry this interaction risk.
Concomitant use can lead to profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, hypotension, and psychomotor impairment. Even at usual doses, the combination can be life-threatening.
Mechanism
Tramadol is an opioid analgesic that binds to mu-opioid receptors, inhibiting pain transmission and causing central nervous system (CNS) depression. Oxazepam is a benzodiazepine that enhances the effect of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, leading to further CNS depression. The synergistic CNS depressant effects of both drugs significantly increase the risk of severe adverse outcomes.
Clinical Management
Due to the severe and potentially fatal risks, co-prescription of tramadol and oxazepam is contraindicated. If alternative therapies are not feasible, and the combination is deemed absolutely necessary, prescribe the lowest effective doses for the shortest possible duration, and closely monitor for respiratory depression and sedation. Educate patients and caregivers on the risks and symptoms of CNS depression.
This combination significantly increases the risk of severe respiratory depression, profound sedation, hypotension, psychomotor impairment, coma, and death. Patients may experience decreased respiratory rate, shallow breathing, extreme drowsiness, confusion, and unresponsiveness.
Mechanism
Codeine, an opioid analgesic, and oxazepam, a benzodiazepine, both exert central nervous system (CNS) depressant effects. When co-administered, their synergistic depressant actions on GABA-A receptors (benzodiazepines) and opioid receptors (opioids) lead to profound and additive CNS depression, particularly affecting the respiratory drive.
Clinical Management
Concomitant use of opioids and benzodiazepines should be avoided due to the high risk of severe adverse outcomes, including respiratory depression and death. If no alternatives are available and co-administration is absolutely necessary, the lowest effective doses should be used for the shortest possible duration, with close monitoring for respiratory depression and sedation. Patients and caregivers must be educated on the risks and signs of CNS depression.
Concomitant use can lead to severe and potentially fatal adverse effects, including profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, bradycardia, hypotension, and diminished protective reflexes. The risk of overdose is significantly increased.
Mechanism
Both hydromorphone (an opioid agonist) and oxazepam (a benzodiazepine) are central nervous system (CNS) depressants. Their co-administration leads to an additive pharmacological effect on GABAergic neurotransmission and opioid receptors, resulting in profound CNS depression. This synergistic depression significantly impairs respiratory drive, leading to hypoventilation and respiratory arrest.
Clinical Management
Concomitant use of hydromorphone and oxazepam is generally contraindicated due to the high risk of respiratory depression and death, as highlighted by an FDA Black Box Warning. If co-administration is unavoidable, patients must be closely monitored for signs of respiratory depression and sedation, with reduced dosages of one or both agents. Naloxone and flumazenil should be readily available, and alternative therapies should be considered.
The primary clinical effects include severe respiratory depression, profound sedation, somnolence, coma, and potentially death. Patients may exhibit decreased respiratory rate, shallow breathing, hypoxemia, hypotension, and impaired psychomotor function.
Mechanism
Oxymorphone, an opioid agonist, and oxazepam, a benzodiazepine, both exert central nervous system (CNS) depressant effects. The co-administration leads to an additive and synergistic depression of the CNS, primarily affecting the gamma-aminobutyric acid (GABA) system for benzodiazepines and opioid receptors for oxymorphone, resulting in profound respiratory depression and sedation.
Clinical Management
Concurrent use of oxymorphone and oxazepam is generally contraindicated due to the high risk. If co-administration is unavoidable, the lowest effective doses of both drugs should be used for the shortest possible duration, with close monitoring for respiratory depression and sedation. Consider alternative therapies that do not involve co-prescribing an opioid and a benzodiazepine.
This interaction significantly increases the risk of severe respiratory depression, profound sedation, hypotension, psychomotor impairment, coma, and death. Patients may experience decreased level of consciousness, bradycardia, pinpoint pupils, and hypoxemia. The combination can also impair cognitive function and coordination, increasing the risk of falls and accidents.
Mechanism
Oxycodone, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia, sedation, and respiratory depression. Oxazepam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to CNS depression. The co-administration of these two CNS depressants results in an additive and synergistic depressant effect on the brainstem respiratory centers and overall CNS activity.
Clinical Management
Concomitant use should generally be avoided due to the high risk of severe adverse outcomes; if absolutely necessary, use the lowest effective doses for the shortest possible duration. Closely monitor patients for signs of respiratory depression and sedation, especially during initiation or dose escalation of either drug. Educate patients and caregivers about the risks and symptoms of CNS depression, and ensure naloxone is available if appropriate.
Patients may experience profound sedation, respiratory depression (decreased respiratory rate and depth), coma, and potentially death. Other symptoms include dizziness, confusion, psychomotor impairment, and hypotension.
Mechanism
Both morphine (an opioid agonist) and oxazepam (a benzodiazepine) are central nervous system (CNS) depressants. Their co-administration leads to additive CNS depression, primarily by enhancing GABAergic neurotransmission (benzodiazepines) and acting on mu-opioid receptors (morphine), resulting in synergistic effects on respiratory drive and sedation.
Clinical Management
Avoid co-prescription if possible. If concomitant use is unavoidable, prescribe the lowest effective doses for the shortest duration possible, monitor closely for respiratory depression and sedation, and educate patients and caregivers on the risks and symptoms. Consider naloxone availability for patients at high risk.
Patients may experience profound sedation, respiratory depression (decreased respiratory rate and depth), hypoxia, hypotension, psychomotor impairment, and altered mental status. In severe cases, this can progress to coma, brain injury, and death due to respiratory arrest. The risk is heightened in opioid-naive patients or those with underlying respiratory conditions.
Mechanism
Both methadone, an opioid agonist, and oxazepam, a benzodiazepine, are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, particularly affecting the brainstem respiratory centers, leading to reduced respiratory drive and potentially severe hypoventilation. This synergistic effect increases the risk of respiratory depression, profound sedation, and coma.
Clinical Management
Avoid concomitant use of methadone and oxazepam whenever possible. If co-prescription is unavoidable, use the lowest effective doses for the shortest duration possible, and closely monitor patients for signs of respiratory depression and sedation. Educate patients and caregivers about the risks, and ensure naloxone is available if appropriate. Consider alternative non-opioid or non-benzodiazepine therapies.
Patients may experience severe sedation, respiratory depression (ranging from hypoventilation to respiratory arrest), profound hypotension, coma, and death. Other symptoms include dizziness, confusion, psychomotor impairment, and unresponsiveness.
Mechanism
Both tapentadol (an opioid analgesic) and oxazepam (a benzodiazepine) are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, primarily by enhancing GABAergic neurotransmission (benzodiazepines) and activating mu-opioid receptors (tapentadol), leading to profound respiratory and CNS depression.
Clinical Management
Avoid concomitant use of tapentadol and oxazepam due to the high risk of severe adverse outcomes. If co-administration is unavoidable, prescribe the lowest effective doses for the shortest possible duration, and monitor patients closely for respiratory depression and sedation. Educate patients and caregivers on the risks and symptoms of CNS depression.
For complete prescribing information:
View full OXAZEPAM monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.